3TR Research on Lupus Spotlighted in IHI’s 2024 Annual Report Summary

3TR researchers have, for the first time, identified molecular signalling pathways that reliably distinguish between flare phases, low disease activity, and remission in lupus – a chronic autoimmune disease affecting around half a million people in Europe.

The analysis used transcriptomic data from 321 patients, taken from the larger PRECISESADS dataset of 2,000 individuals, and revealed molecular markers linked to disease activity. These results open new perspectives for more precise monitoring and, ultimately, improved management of lupus.

Read the full article here.